Abstract The autosomal recessive polycystic kidney disease (ARPKD) gene, PKHD1, has been implicated in the genesis or growth of colorectal adenocarcinoma, as a high level of somatic mutations was found in colorectal tumor tissue. To determine whether carriers of a single PKHD1 mutation are at increased risk of colorectal carcinoma, we assessed the prevalence of the commonest European mutation, T36M. First, we assayed a European cohort of ARPKD patients and found T36M was responsible for 13.1% of mutations. We then investigated two European cohorts with colorectal adenocarcinoma versus two control cohorts of similar age and gender. Screening for the most common PKHD1 mutation, T36M, we detected 15:3,603 (0.42%) controls versus 1:3,767 (0.027%) colorectal cancer individuals, indicating that heterozygous PKHD1 mutations are not a risk factor and are protective (p = 0.0002). We also show that the carriage rate for PKHD1 mutations in the European population is higher than previous accepted at 3.2% (1:31 genomes).
Introduction
Autosomal recessive polycystic kidney disease (ARPKD) is characterized by dilation of collecting ducts (CDs) in the kidney and hepatic fibrosis with or without non-obstructive biliary dilatation. ARPKD is most often present in utero or at birth with the finding of marked renal enlargement, due to cysts, and biliary dysgenesis. The disease is characterized by loss of epithelial polarity and dedifferentiation of the cells lining the biliary tree and CD of the kidney. ARPKD is due to mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene and is recessive with heterozygote 'carriers' being phenotypically normal. PKHD1 has also been implicated in the genesis or growth of colon adenocarcinoma. In a high throughput screen of 14,661 human protein coding transcripts, PKHD1 was found to be the seventh most common somatically mutated gene in colorectal cancer cases (Sjoblom et al. 2006 ). There has been debate on whether some of the genes described as candidate cancer genes (CAN) in the above study are truly mutated above background levels. PKHD1 initially appeared to be a CAN gene (CAN score 3.5), but in the The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFRs, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CFR.
face of more stringent criteria failed to reach statistical significance (Chng 2007; Forrest and Cavet 2007; Getz et al. 2007; Loeb and Bielas 2007; Rubin and Green 2007) . However, the finding that a gene known to be involved in the control of epithelial differentiation was somatically mutated in 5 of 35 colon tumors (14.2%) is of interest. A prediction from this study is that individuals carrying a germline PKHD1 mutation are at enhanced risk of colorectal cancer. In the European-derived population, T36M is the most common mutant allele (always a 107 C ? T transition, Ward et al. 2002) responsible for approximately 17.6% of all PKHD1 mutations (Bergmann et al. 2005) ; other described mutations are individually rare or only more common in specific populations (Consugar et al. 2005; Rossetti et al. 2003) . Homozygotes with the M36 allele genotype uniformly develop ARPKD which may be severe, implying that this allele significantly disrupts the normal function of the ARPKD protein, fibrocystin (Rossetti et al. 2003) . ARPKD affects about 1:20,000 neonates (this is an approximate and conservative estimate, with incidences of 1:40,000 quoted elsewhere; Zerres et al. 1984) , and thus, a carrier rate of 1:70 has been suggested for genetic counseling. On this basis, the T36M allele is predicted to be present in about 1:412 European genomes. This presents a testable hypothesis, whether T36M carriers have an increased risk of colorectal carcinoma. A prevalence of 1:412 is within the range that can be assessed in our large colorectal cancer cohort. Since the precise carrier frequency of PKHD1 mutations is unknown, we also used this study to better estimate the frequency of all PKHD1 mutations in Europeans.
Results
Initially, we developed a TaqMan assay (Applied Biosystems, Foster City, CA) for the T36M allele and assessed its prevalence in a cohort of European-derived ARPKD patients. This served to both validate the assay and supply a baseline T36M prevalence rate in an ARPKD patient cohort, a sample of individuals with classical ARPKD and their parents (Rossetti et al. 2003) . In our cohort, we derived an allele frequency of 13.1%, 95% CI 8.9-18.8% (n = 183). The total number of alleles is an odd number, because in one case we only had one parent and no DNA from an affected individual. The 95% confidence level overlaps with the 17.6% incidence rate observed by others (Bergmann et al. 2005) . All mutations were confirmed by sequencing.
We next screened 1,842 subjects with a history of sporadic colorectal adenocarcinoma (US residents of European origin) and 1,601 clinic-based control subjects (similar in age, gender and state of residence to the cancer cohort), see Table 1 . Six T36M heterozygotes were found in the control sample (0.37%), and none (0.0%) in the colorectal cancer sample (p = 0.01 Fisher's exact test).
To confirm the initial study, which showed an unexpected protective effect of T36M on colorectal cancer, we assembled a new cohort of control and colorectal cancer patients (of European origin) with no overlap with the initial sample. In this second study, we found nine T36M heterozygotes in the control sample (0.45%, n = 2,002 subjects) and one in the colorectal cancer sample (0.05%, n = 1,925 subjects; p = 0.022). This individual was 36M rate per allele (95% CI) 0.22% (0.11-0.45%) 0.026% (1.35e-3 to 0.17%) 0.21% (0.12-0.35%) 0.013% (6.9e-4 to 0.086%) 36M rate per subject 0.45%* 0.05%* 0.42%*** 0.03%*** * The difference between the control and cancer sample is significant at p = 0.02 (Fisher's exact test) ** The difference between the control and cancer sample is significant at p = 0.01 (Fisher's exact test) *** The difference between the combined control and cancer sample is significant at p = 0.0002 (Fisher's exact test). Odds ratio = 0.072, 95% CI 0. 003-0.36 confirmed to have stage 3 colorectal carcinoma. Together, the data show that the prevalence of T36M is 15:3,603 (0.42%) in the control and 1:3,767 (0.027%) in the colorectal sample (p = 0.0002; Table 1 ). This indicates that the T36M allele is not associated with an increased risk of colon cancer; indeed, the opposite hypothesis that the T36M mutation is protective becomes extremely significant, with an odds ratio = 0.072, 95% CI 0.003-0.36. To calculate the carriage rate of all PKHD1 mutations in the European sample, we used the allelic incidence of T36M of 1:480 alleles (0.42% of genomes) in controls and the incidence of T36M in our ARPKD sample (1 in 7.6 PKHD1 mutations is T36M, 13.1%), to project a 3.2% (7.6 9 0.42), 1:31 carrier frequency for PKHD1 in the European population (3.2%, 95% CI 1.7-5.9%). The previous estimate of ARPKD mutation carrier rate is 1:70 or 1.43%, which is just outside the 95% confidence limits of our study. These 16 T36M heterozygotes were confirmed by Dye-terminator DNA sequencing.
Discussion
PKHD1 has been implicated in the genesis of colorectal carcinoma by high throughput sequencing of 120,839 coding exons of the human genome in normal somatic tissue and colorectal tumors. This screen detected mutations in the known CAN genes, APC (CAN score [ 10), KRAS ([10), TP53 ([10), FBXW7 (5.1), SMAD4 (4.6) and MLL3 (3.7), all of which are tumor suppressors or proteins activated in carcinogenesis. PKHD1 has a CAN score of 3.5, tied as the 7th highest CAN score with GUCY1A2 and EPHB6. Based on these data, we predicted that PKHD1 mutations would enhance susceptibility to colorectal carcinoma. However, our data appear to run counter to this and suggests that PKHD1 mutation carriers may be protected from colorectal cancer. One possible hypothesis to explain the findings is that reduction of fibrocystin activity might result in enhanced mitotic instability which paradoxically inhibits carcinogenesis. It has recently been shown that fibrocystin localizes to the centrosome in a range of kidney cell lines and that depletion of fibrocystin in IMCD3 and MDCK results in centrosome amplification, chromosome lagging and multipolar spindle formation. Centrosome amplification was also observed in ARPKD kidneys (Zhang et al. 2010) . Such alterations in karyotypic stability would be predicted to be oncogenic. However, mutations in genes involved in mitotic segregation of chromosomes, but which have no role in DNA metabolism or repair (such as the centromere-linked protein CENP-E), induce aneuploidy without DNA damage and have a complex effect on tumor development. Cenp ?/-mice with pure aneuploidy develop lymphomas and lung tumors at an enhanced rate in aged mice; however, the same genotype can suppress chemically or genetically induced tumor formation (Weaver et al. 2007 ). It may be that germline mutations in PKHD1 act similarly, inducing susceptibility to centrosomal amplification in certain contexts, so that pre-malignant cells have too much genomic instability to form aggressive tumors (undergoing mitotic catastrophe and apoptosis), accounting for the protective effect of the T36M PKHD1 mutation for the development of colorectal carcinoma.
Methods

Gene-based mutation screening
Genotyping was carried out using TaqMan genotyping assay (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Specifically, 20 ng of genomic DNA was used in 5 ll total volume of PCR reaction. Primers and probes were custom designed and purchased through Applied Biosystems. Products of 87 bp were amplified using Taqman Genotyping Master Mix (Applied Biosystems) combined with the TaqMan assay mix consisting of two allele specific probes and a pair of PCR primers (forward primer-CGTCACCTGAGTTTA CATATTGAACCT; reverse primer-CCCCAACCTAC CATCAAAAATGACT). Samples were run at 95°C for 10 min followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. The allele detecting probes were VIC-labeled ATCCACGTTCCCCC (T36) and FAM-labeled ATCC ACATTCCCCC (M36). Following PCR amplification, the allele specific signals were measured on the ABI Prism 7900 using Sequence Detection Software 2.3 (Applied Biosystems). The quality value is calculated using Applied Biosystems' proprietary calling algorithm. Genotyping Quality value was at least 95%. Internal controls were sequence verified WT, T36M and M36 genomic DNAs.
Human subjects IRB approval was obtained for the analysis performed in this study and 08-007049 for control DNA samples and IRB# 622-00; 332-94 and 806-96 for the genomic DNAs from subjects with colorectal cancer).
ARPKD patients ARPKD patients of European origin were collected mainly from the US and Spain, as previously defined. Patients were included only if they had mutation proven ARPKD or a typical ARPKD phenotype (Rossetti et al. 2003) .
Cases
Colon cancer cases were selected from three prospective collections. The first, the Biobank for Gastrointestinal Health Research, is an ongoing IRB approved collection of biospecimens from participants with normal colonoscopic examinations, colon polyps or colon and rectal cancer seen at Mayo Clinic Rochester between the years of 1995-1998 and 2000 to the present (mean age = 63.2; 58% males). The second group was derived from a subset of the North Central Cancer Treatment Group (NCCTG) clinical trial NO147. Cases for the clinical trial were enrolled at over 65 NCCTG sites in the US and Canada, which included Mayo Clinic (Rochester, Arizona, and Florida). As part of the clinical trial protocol, biospecimens were collected in the beginning of March 2004. Patients aged C 18 years with histologically confirmed and surgically removed stage III colon cancer were eligible. Of the consented patients, only US resident Europeans were included in this study (mean age = 64.4; 55% males). Proximal colon tumors included those arising in the cecum, the ascending, and transverse colon (including both flexures). Distal tumors were defined as those occurring in the descending or sigmoid colon. The third group of cases utilized originated from the Colon Cancer Family Registry, an international consortium of six centers in North America and Australia collaborative resource described in more detail by Newcomb et al. (2007) , which collected both CRC cases from family clinics, population-based sampling from incident cases of CRC and population-based recruitment of patients with younger age of cancer onset while non-blood relative and/ or spousal controls were collected from these centers (mean age = 49.9; 51% males).
Controls
Clinic-based controls were collected from the Biobank for Gastrointestinal Health Research via the clinical core of the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567), the Colon Cancer Family Registry, the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701), and the Mayo Clinic Biobank. Controls of European descent from the Biobank for Gastrointestinal Health Research (consented subjects with normal colonoscopies and no prior polyp or cancer history; mean age = 64.2; 56% males) and the Colon Cancer Family Registry are described above in more detail (mean age = 50.7; 49% males). The control group provided by the prospective collection of the Mayo Clinic SPORE in Pancreatic Cancer was derived from consented subjects who had been seen for a routine annual general physical examination in the Department of Medicine, Mayo Clinic, Rochester, MN, since 2000-2008 (mean age = 61.2; 46% males; McWilliams et al. 2005) . Initiated in 2009, the Mayo Clinic Biobank controls are subjects from Olmsted County found to be healthy during a medical examination and in the Department of Medicine divisions of Community Internal Medicine, Family Medicine and General Internal Medicine (mean age = 50.4; 51% males). For all control subjects, none had a history of cancer at the time of enrollment and all were of European descent.
Overall, there were 1,483 cases ascertained from the two sources described in the previous section: Biobank for Gastrointestinal Health Research (N = 834) and NCCTG_N0147 (N = 649). One hundred and ten individuals of non-Caucasian ancestry, 60 patients not from the continental US, and 6 others not meeting other inclusion criteria were excluded from this study. Of the 1,307 available cases, 1,244 were matched on age, gender and state of residence to the general medicine controls (all Caucasian). DNA was not available for 129 cases and 235 controls. This yielded 1,178 cases, to which another 693 sporadic colorectal cancer genomic DNA samples were added. Genotyping was performed on a total of 1,871 cases (29 failures to amplify 1.6%) and 1,621 controls (20 failures to amplify 1.2%).
Statistics
Confidence levels were computed using the central confidence interval calculator at http://www.causascientia.org/ math_stat/ProportionCI.html, and the Fisher's exact test using the calculator at http://www.langsrud.com/fisher.htm or the R statistics package, http://www.r-project.org/.
